LAVA Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference
PremiumPress ReleasesLAVA Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference
2M ago
LAVA Announces Annual Meeting of Shareholders
Premium
Press Releases
LAVA Announces Annual Meeting of Shareholders
3M ago
LAVA Therapeutics’ Innovative Gammabody® Cancer Therapy
Premium
Company Announcements
LAVA Therapeutics’ Innovative Gammabody® Cancer Therapy
3M ago
LAVA Therapeutics Announces Progress and Stability
PremiumCompany AnnouncementsLAVA Therapeutics Announces Progress and Stability
5M ago
LAVA Provides Business Updates and  Reports Fourth Quarter and Year-End Financial Results
Premium
Press Releases
LAVA Provides Business Updates and Reports Fourth Quarter and Year-End Financial Results
5M ago
Lava Therapeutics reports Q4 EPS (24c), consensus (12c)
Premium
The Fly
Lava Therapeutics reports Q4 EPS (24c), consensus (12c)
5M ago
LAVA Therapeutics Announces Collaboration with Merck & Co., Inc., Rahway, NJ, USA to Evaluate LAVA-1207 in Combination with KEYTRUDA®
PremiumPress ReleasesLAVA Therapeutics Announces Collaboration with Merck & Co., Inc., Rahway, NJ, USA to Evaluate LAVA-1207 in Combination with KEYTRUDA®
7M ago
Lava Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results
Premium
Press Releases
Lava Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results
9M ago
Lava Therapeutics reports Q3 EPS (34c), consensus (49c)
Premium
The Fly
Lava Therapeutics reports Q3 EPS (34c), consensus (49c)
9M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100